FDA’s ICH M15 notice puts model-informed evidence into the harmonised dossier conversation

FDA’s availability notice for ICH M15 is more than a technical update for pharmacometric specialists. It marks a harmonised framework for how model-informed drug development (MIDD) evidence should be planned, assessed, documented, discussed with regulators and presented in submissions. For sponsors, the practical message is that model-derived evidence is being placed into a more structured regulatory framework. The Federal Register notice says M15 provides general recommendations for planning, model evaluation and documentation of MIDD evidence; establishes a harmonised assessment framework and terminology; and addresses related regulatory interactions, reporting and submission. ## The policy signal M15 points toward common expectations for the life cycle of model-informed evidence: not just whether a model is scientifically useful, but how its purpose, evaluation and evidentiary role are explained in the regulatory record. That matters because harmonisation changes the dossier problem. If terminology and assessment concepts are aligned through ICH, sponsors have less room to treat modelling packages as bespoke attachments. The model rationale, evaluation approach, documentation and submission narrative need to be coherent enough to fit a shared regulatory language. The M15 notice also sits alongside FDA’s availability of ICH Q9(R1) on quality risk management. Together, the two guidances show FDA continuing to make ICH-developed principles available in areas that affect core development and submission disciplines: risk management on the quality side and model-informed evidence on the drug-development side. ## Who should care

This is most directly relevant to drug sponsors that use MIDD evidence in development or submissions. It is also relevant to regulatory affairs, clinical pharmacology, pharmacometrics, biostatistics, clinical development and submission publishing teams that must turn technical model work into reviewable evidence. Quality and CMC teams should also note the parallel FDA availability of ICH Q9(R1), because it reinforces the continuing role of ICH quality risk management principles in the US guidance landscape. ## Practical watchpoints Sponsors should pressure-test whether MIDD work is ready to be described under the elements highlighted in M15: - Planning: define the intended role of MIDD evidence early enough that the model work can support the regulatory question it is meant to address. - Model evaluation: ensure the evaluation approach is documented in a way that supports the claimed use of the model-derived evidence. - Documentation: avoid leaving key assumptions, methods or evidentiary claims implicit; M15 specifically points to documentation of MIDD evidence. - Terminology: align internal and submission language with the harmonised assessment framework and associated terminology described in the notice. - Regulatory interactions: prepare to discuss MIDD evidence in a structured way during relevant interactions with regulators. - Reporting and submission: treat model-informed evidence as part of the dossier narrative, not only as a technical appendix. ## What to monitor next The next implementation question is how sponsors translate M15’s general principles into repeatable submission practices: templates, review checklists, meeting materials and documentation standards for MIDD evidence. Regulatory teams should also monitor how FDA continues to make ICH guidances available across development and quality disciplines, including how M15 and Q9(R1) are incorporated into internal regulatory strategies. ## Sources - S1 — FDA, “Q9(R1) Quality Risk Management May 2023” - S2 — Federal Register, “M15 General Principles for Model Informed Drug Development; International Council for Harmonisation; Guidance for Industry; Availability”